



Corrigendum

Corrigendum to “Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest”

Anngela C. Adams^a, Anne M. Macy^a, Paul Kang^b, Karla F. Castro-Ochoa^a,
E. M. Kithsiri Wijeratne^c, Ya-Ming Xu^c, Manping X. Liu^c, Alexandra Charos^d,
Marcus W. Bosenberg^d, A.A. Leslie Gunatilaka^{c,e}, Aparna R. Sertil^{a,*}, K. Taraszka Hastings^{a,e,*}

^a University of Arizona College of Medicine Phoenix, 425 N. 5th St., Phoenix, AZ 85004, United States

^b Mel and Enid Zuckerman College of Public Health, 714 E. Van Buren St., Phoenix, AZ 85006, United States

^c Southwest Center for Natural Products Research, School of Natural Resources and the Environment, College of Agriculture and Life Sciences, University of Arizona, 250 E. Valencia Rd., Tucson, AZ 85706, United States

^d Department of Dermatology, Yale University, 333 Cedar St., New Haven, CT 06520, United States

^e University of Arizona Cancer Center, University of Arizona, 1515 N. Campbell Ave., Tucson, AZ 85724, United States

The authors regret inadvertent errors in the methods for the in vivo monoclonal antibody treatment, specifically the monoclonal antibody dose and the isotype control clone. In the Materials and methods section on in vivo treatment, the sentence on anti-PD-1 treatment should read: For evaluation of the efficacy of PCC in combination with anti-PD-1 mAb, mice were treated with 1) vehicle control IT daily for 15 doses and 10 mg/kg rat IgG2a, κ isotype control mAb (BioXCell, Lebanon, NH, Cat. No. BE0089, clone 2A3) intraperitoneal (IP) every three days for the duration of the experiment; 2) PCC 20 mg/kg IT daily for 15 doses; 3) 10

mg/kg anti-PD-1 mAb (BioXCell, Cat. No. BE0146, clone RMP1-14) IP every three days for the duration of the experiment; or 4) PCC 20 mg/kg IT daily for 15 doses and 10 mg/kg anti-PD-1 IP every three days for the duration of the experiment. The sentence in the legend for Figure 4E should read: Mice treated with anti-PD-1 received 10 mg/kg IP every three days, starting on day 1 for the duration of the experiment.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.tranon.2021.101259>

DOI of original article: <https://doi.org/10.1016/j.tranon.2021.101259>.

* Corresponding author.

E-mail addresses: arsertil@arizona.edu (A.R. Sertil), khasting@arizona.edu (K.T. Hastings).

<https://doi.org/10.1016/j.tranon.2022.101446>

Available online 19 May 2022

1936-5233/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

